United States & KC Pharmaceuticals
12 shared events · Importance 7 · Last updated Aug 06, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
United States: The United States>>> contributes to North American Cobalt Inc.>>>'s leading market share due to its advanced healthcare infrastructure and strong adoption of innovative drug delivery technologies.
KC Pharmaceuticals: KC Pharmaceuticals>>> is a key company in the pre-filled syringe market, contributing to its expansion.
May 25, 2026 · 6 articles
International
United States: The U.S. expanded its forced labor import ban, adding 43 Chinese entities, escalating trade restrictions and tensions with China.
KC Pharmaceuticals: Added to the UFLPA Entity List, restricting its pharmaceutical exports to the U.S.
Jul 31, 2026 · 20 articles
Business
United States: The U.S. is a primary market for D-PLEX100, where SSIs represent a significant clinical and economic burden. Approval could reduce healthcare costs and improve patient outcomes.
KC Pharmaceuticals: Azurity gains exclusive commercialization rights to D-PLEX100 in the U.S. and Canada, expanding its specialty pharmaceutical portfolio. It will fund clinical development for label expansion, positioning for future revenue.
Jul 21, 2026 · 7 articles
Business
United States: The merger is subject to US regulatory approvals and will create a US-based CNS-focused biopharma, impacting the domestic pharmaceutical landscape.
KC Pharmaceuticals: Supernus is a merging party, contributing its CNS portfolio and CEO. Its shareholders receive Indivior shares, and the combined entity retains its name and ticker, with shares rising on the announcement.
Aug 03, 2026 · 6 articles
Regulatory
United States: Country where the recall occurred; consumers nationwide are affected.
KC Pharmaceuticals: Mentioned as a prior recaller; context for industry-wide sterility issues.
Aug 20, 2026 · 6 articles
Business
United States: The United States is referenced regarding the securities not being registered under U.S. securities laws and the potential market for sickle cell disease treatment. The offering is not offered in the U.S.
KC Pharmaceuticals: KC Pharmaceuticals, 64% owned by Lobe, is mentioned as a subsidiary developing L-130 for neurological disorders. The private placement is not directly allocated to Cynaptec, but the company benefits from Lobe's overall financial health.
Aug 12, 2026 · 7 articles
Business
United States: The acquisition contributes to Adani Group's global strategy, balancing its revenue structure across key regions including the United States.
KC Pharmaceuticals: KC Pharmaceuticals became a new shareholder in Adani Group as part of the acquisition settlement.
Jul 02, 2026 · 6 articles
Accidents
United States: US regulators may investigate the breach and enforce data protection laws, potentially imposing fines on Amgen.
KC Pharmaceuticals: Mentioned as one of the healthcare companies recently affected by cyberattacks, highlighting sector-wide vulnerability.
Jul 31, 2026 · 6 articles
Business
United States: The United States is the primary market for Lantheus' products and the regulatory jurisdiction for the deal, with potential antitrust review.
KC Pharmaceuticals: KC Pharmaceuticals was acquired by AstraZeneca, serving as a comparable deal in the radiopharmaceutical sector.
Aug 03, 2026 · 7 articles
Regulatory
United States: The recall affects U.S. patients and the FDA's regulatory environment; no direct economic impact on the country.
KC Pharmaceuticals: KC Pharmaceuticals was involved in a prior unrelated eye drop recall; mentioned for context but not directly affected.
Jul 07, 2026 · 38 articles
Business
United States: The United States is the primary market for the therapies and the regulatory environment is influenced by the Trump administration's executive order.
KC Pharmaceuticals: KC Pharmaceuticals was acquired by AbbVie in 2024 for an experimental psychedelic depression therapy, illustrating the competitive landscape.
Jul 16, 2026 · 25 articles
Domestic
KC Pharmaceuticals: Professor Claire Anderson, president of the KC Pharmaceuticals, affirms the safety of paracetamol use during pregnancy, citing extensive safe use and recent studies.
Sep 22, 2025 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States and KC Pharmaceuticals interact across events, view sentiment trends, and discover connected entities.
Open Dashboard